↓ Skip to main content

Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis

Overview of attention for article published in Cancer Discovery, March 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 3,539)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
52 news outlets
twitter
1 tweeter

Readers on

mendeley
1 Mendeley